ZICONOTIDE ACETATE

Description
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021060s006lbl.pdf | https://www.ncbi.nlm.nih.gov/pubmed/15578997

Ziconotide (PRIALT; SNX-111) is a neuroactive peptide, which was approved by FDA in 2004 for the management of severe chronic pain in adult patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. Ziconotide acts as a selective N-type voltage-gated calcium channel blocker, which leads to a blockade of excitatory neurotransmitter release from the primary afferent nerve terminals.

CNS Activity

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Voltage-dependent N-type calcium channels 2 Target ID: Voltage-dependent N-type calcium channels Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021060s006lbl.pdf \| https://www.ncbi.nlm.nih.gov/pubmed/15578997	Blocker 537

Conditions

Condition	Modality	Targets	Highest Phase	Product
severe chronic pain 2 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/021060s006lbl.pdf	Primary		Approved 8429	PRIALT Approved Use PRIALT (ziconotide) solution, intrathecal infusion is an N-type calcium channel antagonist indicated for the management of severe chronic pain in patients for whom intrathecal therapy is warranted, and who are intolerant of or refractory to other treatment, such as systemic analgesics, adjunctive therapies, or intrathecal morphine. Launch Date 1.10419195E12

PubMed

Title	Date	PubMed
Neuronal calcium channel antagonists. Discrimination between calcium channel subtypes using omega-conotoxin from Conus magus venom.	1987 Apr 21	2441741
Pharmacological characterization of recombinant N-type calcium channel (Cav2.2) mediated calcium mobilization using FLIPR.	2006 Sep 14	16844100
Pharmacological Inhibition of Voltage-gated Ca(2+) Channels for Chronic Pain Relief.	2013 Dec	24396337

Sample Use Guides

In Vivo Use Guide

PRIALT (ziconotide) solution is intended for administration by or under the direction of a physician experienced in the technique of intrathecal administration and who is familiar with the drug and device labeling. PRIALT may be used for therapy undiluted (25 mcg/mL in 20 mL vial) or diluted (100 mcg/mL in 1 or 5 mL vials). The 100 mcg/mL formulation may be administered undiluted once an appropriate dose has been established.

Route of Administration: Other

Substance Class	Protein Created by `admin` on `Fri Dec 15 16:05:52 UTC 2023` Edited by `admin` on `Fri Dec 15 16:05:52 UTC 2023`
Protein Sub Type
Sequence Type	COMPLETE
Record UNII	T2I226K69M
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ZICONOTIDE ACETATE

Common Name

English

SNX-111 ACETATE

Code

English

ZICONOTIDE ACETATE [MART.]

Common Name

English

PRIALT

Brand Name

English

ZICONOTIDE ACETATE [ORANGE BOOK]

Common Name

English

Ziconotide Acetate [WHO-DD]

Common Name

English

.OMEGA.-CONOTOXIN M VIIA, ACETATE (SALT)

Common Name

English

.OMEGA.-CONOTOXIN M VIIA ACETATE

Common Name

English

CYS-LYS-GLY-LYS-GLY-ALA-LYS-CYS-SER-ARG-LEU-MET-TYR-ASP-CYS-CYS-THR-GLY-SER-CYS-ARG-SER-GLY-LYS-CYS-NH2 ACETATE

Common Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2198